RT Journal Article
T1 Motor Fluctuations Development Is Associated with Non-Motor Symptoms Burden Progression in Parkinson's Disease Patients: A 2-Year Follow-Up Study.
A1 Santos-García, Diego
A1 de Deus Fonticoba, Teresa
A1 Bartolomé, Carlos Cores
A1 Painceiras, Maria J Feal
A1 Castro, Ester Suárez
A1 Canfield, Héctor
A1 Miró, Cristina Martínez
A1 Jesús, Silvia
A1 Aguilar, Miquel
A1 Pastor, Pau
A1 Planellas, Lluís
A1 Cosgaya, Marina
A1 Caldentey, Juan García
A1 Caballol, Nuria
A1 Legarda, Ines
A1 Hernández-Vara, Jorge
A1 Cabo, Iria
A1 Manzanares, Lydia López
A1 Aramburu, Isabel González
A1 Rivera, Maria A Ávila
A1 Mayordomo, Víctor Gómez
A1 Nogueira, Víctor
A1 Puente, Víctor
A1 García-Soto, Julio Dotor
A1 Borrué, Carmen
A1 Vila, Berta Solano
A1 Sauco, María Álvarez
A1 Vela, Lydia
A1 Escalante, Sonia
A1 Cubo, Esther
A1 Padilla, Francisco Carrillo
A1 Castrillo, Juan C Martínez
A1 Alonso, Pilar Sánchez
A1 Losada, Maria G Alonso
A1 Ariztegui, Nuria López
A1 Gastón, Itziar
A1 Kulisevsky, Jaime
A1 Estrada, Marta Blázquez
A1 Seijo, Manuel
A1 Martínez, Javier Rúiz
A1 Valero, Caridad
A1 Kurtis, Mónica
A1 de Fábregues, Oriol
A1 Ardura, Jessica González
A1 Redondo, Ruben Alonso
A1 Ordás, Carlos
A1 Díaz, Luis M López
A1 McAfee, Darrian
A1 Martinez-Martin, Pablo
A1 Mir, Pablo
A1 Coppadis Study Group, 
K1 Parkinson’s disease
K1 burden
K1 follow-up
K1 motor fluctuations
K1 non-motor symptoms
AB Objective: The aim of the present study was to analyze the progression of non-motor symptoms (NMS) burden in Parkinson's disease (PD) patients regarding the development of motor fluctuations (MF). Methods: PD patients without MF at baseline, who were recruited from January 2016 to November 2017 (V0) and evaluated again at a 2-year follow-up (V2) from 35 centers of Spain from the COPPADIS cohort, were included in this analysis. MF development at V2 was defined as a score ≥ 1 in the item-39 of the UPDRS-Part IV, whereas NMS burden was defined according to the Non-motor Symptoms Scale (NMSS) total score. Results: Three hundred and thirty PD patients (62.67 ± 8.7 years old; 58.8% males) were included. From V0 to V2, 27.6% of the patients developed MF. The mean NMSS total score at baseline was higher in those patients who developed MF after the 2-year follow-up (46.34 ± 36.48 vs. 34.3 ± 29.07; p = 0.001). A greater increase in the NMSS total score from V0 to V2 was observed in patients who developed MF (+16.07 ± 37.37) compared to those who did not develop MF (+6.2 ± 25.8) (p = 0.021). Development of MF after a 2-year follow-up was associated with an increase in the NMSS total score (β = 0.128; p = 0.046) after adjustment to age, gender, years from symptoms onset, levodopa equivalent daily dose (LEDD) and the NMSS total score at baseline, and the change in LEDD from V0 to V2. Conclusions: In PD patients, the development of MF is associated with a greater increase in the NMS burden after a 2-year follow-up.
SN 2075-4418
YR 2022
FD 2022-05-05
LK http://hdl.handle.net/10668/20962
UL http://hdl.handle.net/10668/20962
LA en
DS RISalud
RD Apr 19, 2025